Search Results

Seqirus brings multifaceted expertise to influenza prevention, employing both egg and cell-based technologies to meet the global community's needs.

https://www.seqirus.us/expertise

Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.

https://www.seqirus.us/our-company/leadership

Our leadership team is composed of experienced professionals with deep scientific expertise and a shared commitment to public health. Meet them now.

https://www.seqirus.us/our-company/leadership/gregg-sylvester

CSL Seqirus is a global influenza vaccine company developing innovative solutions to ensure epidemic and pandemic preparedness throughout the world.

https://www.seqirus.us/our-company

Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA)

https://www.seqirus.us/news/seqirus-and-us-gov-renew-multi-year-agreement-for-influenza-pandemic-preparedness-and-response

Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives

https://www.seqirus.us/news/seqirus-awarded-us-government-contract-for-two-influenza-vaccines

Read the latest news from Seqirus, a world leader in developing and producing influenza vaccines.

https://www.seqirus.us/news/covid19-update

The University of Queensland, CEPI and CSL partner to advance development and manufacture of COVID-19 vaccine candidate

https://www.seqirus.us/news/the-university-of-queensland-cepi-and-csl-partner-on-covid-19-vaccine-candidate

Afluria QIV is produced by Seqirus Inc., a company with specific expertise in influenza vaccines.

https://www.seqirus.us/-/media/seqirus/pdfs/pregnancy-registry-documents/afluria-informed-consentv10sample.pdf

Seqirus is first-to-market with shipment of seasonal influenza vaccines to the US for the 2016-2017 season

https://www.seqirus.us/news/seqirus-is-first-to-market-with-shipment-of-seasonal-influenza-vaccines-for-2016-2017-season